Article

Cancer Immunotherapy Biomarkers of Response and Toxicity; Current Limitations and Future Promise

2021-12-28

Abstract excerpt

Immune Checkpoint Inhibitors are monoclonal antibodies that are used to treat over one in three cancer patients. While they have changed the natural history of disease, prolonging life and preserving quality of life, they are highly active in less than 40% of patients, even in the most responsive malignancies such as melanoma, and cause significant autoimmune side effects. Licenced biomarkers include tumour Progra...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 99c2da06-54b8-5551-b935-449c1e416be2
DOI: 10.20944/preprints202112.0447.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cancer Immunotherapy Biomarkers of Response and Toxicity; Current Limitations and Future PromiseDOI 10.20944/preprints202112.0447.v1Read

Advances and prospects of biomarkers for immune checkpoint inhibitorsSemantic proximity Read

Large-Scale Meta-Analysis of Potential Biomarkers for Treatment Response to Anti-PD-1/PD-L1 Immune Checkpoint InhibitorsSemantic proximity Read

Microbiome influencers of checkpoint blockade–associated toxicitySemantic proximity Read

Tumors of the Digestive System: Comprehensive Review of Ancillary Testing and Biomarkers in the Era of Precision Medicine.Semantic proximity Read

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategiesSemantic proximity Read

Gut Microbiota–Tumor Microenvironment Interactions: Mechanisms and Clinical Implications for Immune Checkpoint Inhibitor Efficacy in CancerSemantic proximity Read

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockadeSemantic proximity Read

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read

A review on the role of gut microbiota in immune checkpoint blockade therapy for cancerSemantic proximity Read

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer PatientsSemantic proximity Read

Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomesSemantic proximity Read

New Insights Into the Cancer–Microbiome–Immune Axis: Decrypting a Decade of DiscoveriesSemantic proximity Read